Silence Therapeutics presents additional data from phase 1 study of divesiran as potential first-in-class siRNA treatment for polycythemia vera: London Monday, June 16, 2025, 18:0 ...

The poster, “ Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors ,” was presented by Dr. Kasi on Saturday, ...

An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could ...

Eolo Pharma, a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, today announced the publication of its first-in-human study in Nature Metabolism, ...

Innovent completes first patient dosing in seventh phase 3 trial (GLORY-OSA) of mazdutide in China with moderate-to-severe OSA & obesity: San Francisco, US Tuesday, June 17, 2025, ...

Martin Vollmer, biopharma program manager at Agilent Technologies, spoke to LCGC International about the evolving importance of glucagon-like peptide-1 (GLP-1) therapeutics and the challenges they ...

Pfizer undertook a broad pre-clinical program to characterize the pharmacology, pharmacokinetics, metabolism ... Phase 2 clinical trial. Tolimidone is a selective activator of the enzyme Lyn kinase ...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free ...